Microdosed Atropine 0.1% and 0.01% Ophthalmic Solutions for Reduction of Pediatric Myopia Progression
Public ClinicalTrials.gov record NCT03942419. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Double-Masked, Randomized, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of Atropine 0.1% and 0.01% Ophthalmic Solutions Administered With a Microdose Dispenser for the Reduction of Pediatric Myopia Progression (The CHAPERONE Study)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study evaluates the progression of myopia in participants using microdosed atropine 0.01%, atropine 0.1%, or placebo ophthalmic solution. Eligible subjects will administer study medication daily in each eye for 48 months. Efficacy and safety assessments will be performed at visits scheduled for 1, 6, 12, 18, 24, 30 and 36 months after initiation of medication use. Subjects will be re-randomized at the 36 month visit, then followed at 6 month intervals for an additional year.
Study identification
- NCT ID
- NCT03942419
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 438 participants
Conditions and interventions
Conditions
Interventions
- Atropine 0.1% Ophthalmic Solution Drug
- Atropine 0.01% Ophthalmic Solution Drug
- Placebo Ophthalmic Solution Drug
Drug
Eligibility (public fields only)
- Age range
- 3 Years to 12 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2, 2019
- Primary completion
- Oct 30, 2024
- Completion
- Nov 19, 2024
- Last update posted
- Jan 5, 2025
2019 – 2024
United States locations
- U.S. sites
- 18
- U.S. states
- 10
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham School of Optometry | Birmingham | Alabama | 35294 | — |
| Midwestern University | Glendale | Arizona | 85308 | — |
| Canyon City Eyecare | Azusa | California | 91702 | — |
| UC Berkeley | Berkeley | California | 94720 | — |
| Marshall Ketchum University College of Optometry | Los Angeles | California | 90037 | — |
| Ratner Children's Eye Center | San Diego | California | 92093 | — |
| Illinois College of Optometry | Chicago | Illinois | 60616 | — |
| Midwestern University | Downers Grove | Illinois | 60515 | — |
| SUNY College of Optometry | New York | New York | 10036 | — |
| Wake Forest Health Network Ophthalmology - Oak Hollow | High Point | North Carolina | 27262 | — |
| Oculus Research | Raleigh | North Carolina | 27603 | — |
| The Ohio State University - College of Optometry | Columbus | Ohio | 43210 | — |
| Scott & Christie and Associates | Cranberry Township | Pennsylvania | 16066 | — |
| Salus University - The Eye Institute | Philadelphia | Pennsylvania | 19141 | — |
| Primary Eyecare Group | Brentwood | Tennessee | 37027 | — |
| Southern College of Optometry | Memphis | Tennessee | 38104 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | — |
| Virginia Pediatric Eye Center | Virginia Beach | Virginia | 23452 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03942419, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 5, 2025 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03942419 live on ClinicalTrials.gov.